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 がん性疼痛は，腫瘍そのものに起因する疼痛だけでなく，がん治療による疼痛や心因性疼痛な
ど様々な要因によって起こる。特にがんの薬物治療の中心である抗がん薬のあるものは，副作用
として有痛性の末梢神経障害を生じ，患者の QOL の低下だけでなく抗がん薬の減薬や休薬の原
因ともなることから，がん治療の観点から非常に重要な問題となっている。しかし，抗がん薬誘
発末梢神経障害による疼痛の発症機序に関しては未だに不明な点が多く，有効な予防法と治療法
が確立していないのが現状である。これまでに，タキサン系抗がん薬 paclitaxel，白金製剤
oxaliplatin やビンカアルカロイド vincristine を用いた抗がん薬誘発末梢神経障害による疼痛の動
物モデルが作出され，疼痛発生機序や様々な鎮痛薬および鎮痛補助薬の効果が検討されてきた。
近年，新しい種類の抗がん薬であるプロテアソーム阻害薬 bortezomib が開発され，多発性骨髄腫
を中心に用いられている。しかし，抗がん作用の有効性は認められる一方，末梢神経障害による
異常感覚（痺れや感覚障害など）や痛みが頻発する。Bortezomib は比較的新しい抗がん薬である
ため末梢神経障害による異常感覚や疼痛の発生機序に関する研究も少ないのが現状であり，その
ため有効な予防法・治療法も確立されていない。そこで，本研究では，bortezomib 誘発疼痛のマ
ウスモデルを作出し，その特徴について検討するとともに，有効な治療薬の検討を行った。 
 
1. Bortezomib 誘発疼痛のマウスモデルの作出と鎮痛薬の効果 1) 
 Bortezomib（0.03～0.3 mg/kg）をマウスに単回尾静脈内注射することにより，投与後 12 日目を
ピークとする一過性の機械的アロディニア（健常では痛みを生じない非侵害性機械刺激で痛みを
生じる状態）及び機械的痛覚過敏（侵害性機械刺激による痛みが増大した状態）が観察された。
一方，熱及び冷刺激に対しては，過敏反応を示さなかった。機械的アロディニアに一次求心線維
の反応性の変化が関与するか否か調べるために，伏在神経の神経活動を電気生理学的に調べた。
Bortezomib 投与後 12 日目では，非侵害性機械刺激によって誘発される神経発火頻度が対照マウ
スと比較して有意に増加した。一方，自発的な発火頻度及び冷刺激中の発火頻度は，bortezomib
投与マウスで増加傾向を示したが，対照マウスと比較して統計的に有意ではなかった。以上の結
果より，bortezomib 誘発機械的アロディニアの形成が，少なくとも一部は一次求心線維の非侵害
性機械刺激に対する反応性増大に起因することが示唆される。なお，bortezomib 投与後 12 日目
に機械的アロディニアがピークとなったことから，以降の実験は投与後 12 日目に行った。 
 Bortezomib（0.3 mg/kg）誘発機械的アロディニアは，非ステロイド性抗炎症薬 diclofenac（10，
30 mg/kg）では抑制されなかった。一方，オピオイド鎮痛薬 morphine（3，5 mg/kg）は，投与後
30 分をピークとして，bortezomib（0.3 mg/kg）誘発機械的アロディニアを有意に抑制した。
Bortezomib 投薬を受けた患者の疼痛に対してもオピオイドの有効性と非ステロイド性抗炎症鎮
痛薬の無効性が報告されており，bortezomib 投与マウスのアロディニアに対する鎮痛薬の効果は，
臨床の知見と類似していた。したがって，本モデルは，bortezomib 誘発末梢神経障害によるアロ
ディニアの発生機序の解析並びに予防薬・治療薬の薬効評価とその作用機序の解析に有用なモデ
ルであることが示唆される。 
 
2. Bortezomib 誘発機械的アロディニアに対する gabapentin の効果及び作用機序 1) 
 Gabapentinおよびその誘導体の pregabalinは神経障害性疼痛の治療に頻用されている。そこで，
bortezomib 誘発機械的アロディニアに対する gabapentin の効果を検討した。 
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 Bortezomib（0.3 mg/kg）誘発機械的アロディニアは，gabapentin（30，100 mg/kg）の経口投与
により抑制され，その抑制効果のピークは投与後 60 分であった。Gabapentin（30，100 g/site）
の大槽内投与は，溶媒投与対照群と比べ有意に bortezomib 誘発機械的アロディニアを抑制した。
Gabapentin（30，100 g/site）の脊髄クモ膜下腔内投与では抑制傾向を示したが統計的に有意では
なかった。一方，gabapentin（30，100 g/site）の後肢足蹠（アロディニア評価部位局所）内局所
投与は機械的アロディニアにほとんど影響を及ぼさなかった。以上の結果より，gabapentin は主
に脳（特に下位脳幹部）に作用することで bortezomib 誘発機械的アロディニアを抑制したと考え
られる。 
 Gabapentin の鎮痛作用機序としては，脊髄後角への直接作用と下位脳幹部に作用して下行性疼
痛抑制系の活性化を介した脊髄後角における間接的抑制作用が報告されている。また，gabapentin
の脊髄クモ膜下腔内注射で抗アロディニア作用が観察される場合には，一次感覚ニューロンで
Ca チャネル2δ-1 サブユニットの発現レベルの増加が観察されることが報告されている。しかし
ながら，bortezomib（0.3 mg/kg）投与後 12 日目には，皮膚および脊髄，延髄，橋において Ca チ
ャネル2δ-1 サブユニットの発現レベルに変化はなかった。脊髄における2δ-1 サブユニットの発
現レベルに変化が無かったことが，gabapentin の脊髄クモ膜下腔内注射で抗アロディニア効果の
観察されなかったことの一因であると考えられる。 
 Bortezomib 誘発アロディニアに対して gabapentin の大槽内注射が有効であったことから下行性
疼痛抑制系の関与について調べた。6-Hydroxydopamine（6-OHDA，20 g/site）の脊髄クモ膜下腔
内投与により予め脊髄内の noradrenalineを涸渇させておくと bortezomib誘発機械的アロディニア
に対する gabapentin（100 mg/kg，経口）の抗アロディニア作用が有意に抑制された。一方，
5,7-dihydroxytryptamine（5,7-DHT，20 g/site）の脊髄クモ膜下腔内投与により脊髄の serotonin を
予め涸渇させておいても，gabapentin（100 mg/kg，経口）の抗アロディニア作用はほとんど影響
を受けなかった。なお，脊髄の noradrenaline あるいは serotonin の涸渇は bortezomib によるアロデ
ィニアの誘発には影響しなかった。以上の結果は，bortezomib 誘発機械的アロディニアに対する
gabapentin の抗アロディニア作用に下行性ノルアドレナリン作動神経系が関与することを示唆す
る。 
 
3. 抗がん薬誘発機械的アロディニアに対する牛車腎気丸の効果及び作用機序 2,3) 
 牛車腎気丸は，10 種の生薬により構成される漢方方剤である。筋肉痛を始め様々な疼痛に対す
る有効性が報告されている。そこで，bortezomib に加え，他の 3 種の抗がん薬（paclitaxel，oxaliplatin
及び vincristine）で誘発される機械的アロディニアに対する牛車腎気丸の効果を比較検討した。 
 Bortezomib（0.3 mg/kg，静脈内），paclitaxel（5 mg/kg，腹腔内），oxaliplatin（3 mg/kg，腹腔内）
或いは vincristine（0.1 mg/kg，腹腔内）をマウスに投与して機械的アロディニア最大となるそれ
ぞれ投与後 12，14，10 或いは 14 日目に，牛車腎気丸（0.1～1 g/kg）を単回経口投与した。牛車
腎気丸は，bortezomib 及び oxaliplatin で誘発される機械的アロディニアを抑制し，その効果は投
与後 30 分が最大であった。一方，paclitaxel 及び vincristine で誘発される機械的アロディニアは
牛車腎気丸で抑制されなかった。以上の結果より，確立された機械的アロディニアに対する牛車
腎気丸の抑制効果が抗がん薬の種類に依存することと，bortezomib 及び oxaliplatin で誘発される
機械的アロディニアに有効であることが示唆される。 
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 上記 4 種の抗がん薬投与後 1 日目から牛車腎気丸（0.1～1 g/kg）を予防的に 1 日 1 回繰返し投
与し機械的アロディニアの形成に与える影響を検討した。牛車腎気丸の予防的投与により
bortezomib, oxaliplatin 及び paclitaxel で誘発される機械的アロディニアを抑制した。一方 , 
vincristine 誘発の機械的アロディニアは抑制しなかった。これらの結果より，牛車腎気丸の抗が
ん薬投与開始時からの予防的投与は，アロディニアの増大を抑制することが示唆される。 
 牛車腎気丸の抗アロディニア作用への下行性抑制系の関与を調べるために，6-OHDA（20 g/site）
或いは 5,7-DHT（20 g/site）の脊髄クモ膜下腔内投与により脊髄の noradrenaline 或いは serotonin
を涸渇させて牛車腎気丸の抗アロディニア作用への影響を調べた。Bortezomib 誘発機械的アロデ
ィニアに対する牛車腎気丸（1 g/kg）の単回経口投与による抑制作用が，脊髄の noradrenaline あ
るいは serotonin の涸渇により減弱した。以上の結果は，牛車腎気丸による抗アロディニア作用に
下行性ノルアドレナリン作動神経系並びにセロトニン作動神経系の両方の活性化が関与するこ
とを示唆する。 
 
4. 結論 
 本研究により，gabapentin および牛車腎気丸が下行性疼痛抑制系の活性化を介して bortezomib
誘発機械的アロディニアを抑制することが明らかとなった。また，抗がん薬投与直後からの牛車
腎気丸の繰返し投与は抗がん薬誘発末梢神経障害性疼痛の予防につながると考えられる。 
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ABSTRACT 
Bortezomib, an inhibitor of proteasome holoenzyme, is used to treat relapsed and refractory 
multiple myeloma. Peripheral neuropathy is a treatment-limiting adverse effect of bortezomib and 
is very difficult to control. In this study, we examined the efficacy of gabapentin in inhibiting 
bortezomib-induced peripheral neuropathy. Single intravenous injections of bortezomib (0.03–0.3 
mg/kg) dose-dependently induced mechanical allodynia with a peak effect 12 days after injection. 
Bortezomib (0.3 mg/kg) also caused mechanical hyperalgesia, but neither affected thermal 
nociception nor induced cold allodynia. Bortezomib increased the response of the saphenous 
nerve to weak punctate stimulation but not response to cool stimulation of the skin. When 
administered 12 days after bortezomib injection, oral and intracisternal gabapentin markedly 
inhibited mechanical allodynia. Intrathecal, but not intraplantar, gabapentin had a tendency to 
reduce mechanical allodynia. The antiallodynic activity of orally administered gabapentin was 
suppressed by noradrenaline, but not serotonin, depletion in the spinal cord. Bortezomib did not 
affect the expression levels of the calcium channel 2-1 subunit, a high-affinity binding site of 
gabapentin, in the plantar skin, spinal cord, medulla oblongata, and pons. These results suggest 
that gabapentin inhibits bortezomib-induced mechanical allodynia, most likely through the 
activation of the descending noradrenergic system. 
 
Keywords: Bortezomib, gabapentin, allodynia, descending noradrenergic system, noradrenaline 
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Introduction 
Bortezomib, an inhibitor of 26S proteasome holoenzyme, is used to treat relapsed multiple 
myeloma and mantle cell lymphoma (1,2). Adverse effects of bortezomib include peripheral 
neuropathy, asthenia, constipation, diarrhea, nausea, and anorexia (3). Peripheral neuropathy 
occurs in approximately 50% of bortezomib-treated patients (3,4), and 40% of patients with 
peripheral neuropathy complain of dysesthesia (unpleasant abnormal sensation) and/or pain (4). 
Bortezomib-induced dysesthesia and pain tend to have a “stocking and glove” distribution (5). 
The incidence of bortezomib-induced peripheral neuropathy gradually increases and reaches a 
plateau after eight cycles of therapy (6). Peripheral neuropathy is the most common adverse event 
leading to treatment discontinuation (3,6), although it disappears after treatment cessation or a 
decrease of the dose administered (6). 
Several kinds of rodent models of bortezomib-induced peripheral neuropathy have been 
developed and the morphological, histological and neurophysiological changes have been 
analyzed (7–11). However, there is no established standard treatment protocol for 
bortezomib-induced peripheral neuropathy. Gabapentin, an anticonvulsant, has proven to be 
effective in the treatment of painful diabetic neuropathy, postherpetic neuralgia, and other 
neuropathic pain syndromes (12). Recent animal studies showed that gabapentin is effective for 
the treatment mechanical allodynia (13–17), thermal hyperalgesia (16), and cold hyperalgesia 
(18), induced by other chemotherapy agents, including paclitaxel, oxaliplatin, and vincristine. 
Because bortezomib has been recently developed, it is unclear whether gabapentin is effective for 
pain and dysesthesia in bortezomib-induced peripheral neuropathy models. In the present study, 
we therefore examined whether a single administration of bortezomib would cause pain-related 
behaviors in mice and whether gabapentin could inhibit bortezomib-induced pain-related 
behaviors. 
 
 
Materials and methods 
Animals 
Male C57BL/6NCr mice (Japan SLC, Shizuoka, Japan), 6 weeks of age at the beginning of 
the experiments, were used. The mice were housed in a room under controlled temperature 
(21–23°C), humidity (45–65%), and light (lights on from 07:00 to 19:00). Food and water were 
freely available. Procedures involving animals were approved by the Committee for Animal 
Experiments at the University of Toyama and were conducted in accordance with the guidelines 
for investigations of experimental pain in animals published by the International Association for 
the Study of Pain. 
 
Materials 
Bortezomib (Toronto Research Chemicals, Ltd., Toronto, Canada) was dissolved in a 
physiological saline solution containing 0.03% (w/v) mannitol just before use. Gabapentin was 
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synthesized by YS and HT, and dissolved in regular tap water for oral administration and in a 
physiological saline solution for intrathecal, intracisternal, and intraplantar injections. 
6-Hydroxydopamine hydrochloride (6-OHDA, Sigma-Aldrich, St. Louis, MO, USA) and 
5,7-dihydroxytryptamine creatinine sulfate (5,7-DHT, Sigma-Aldrich) were dissolved in a 
physiological saline solution containing 0.1% ascorbic acid. Desipramine hydrochloride 
(Sigma-Aldrich) was dissolved in a physiological saline solution. 
 
Drug administration 
Bortezomib was administered intravenously. The regular clinical dose of bortezomib is 5.2 
mg/m2 body surface area per cycle (1.3 mg/m2 is administered intravenously four times for 2 
weeks). If body height and weight are 170 cm and 60 kg, respectively, body surface area is 1.69 
m2, according to Du Bois's formula for calculating the body surface area. Therefore, the total dose 
to administer is 8.8 mg per person or 0.15 mg/kg. Thus, in this study, bortezomib was 
administered at doses of 0.03 to 0.3 mg/kg. Higher doses of bortezomib were not examined 
because of its limited solubility in the vehicle. 
Gabapentin was administered orally, intracisernally, intrathecally, and intraplantarly 12 days 
after bortezomib administration. For depletion of monoamines in the spinal cord, 6-OHDA (20 
μg/mouse) and 5,7-DHT (20 μg/mouse) were injected intrathecally 9 days after bortezomib 
administration. Desipramine hydrochloride was injected intraperitoneally 30 min before 5,7-DHT 
injection to block 5,7-DHT uptake into the noradrenergic nerve terminals (19). The volume of 
intravenous, oral, and intraperitoneal injections was 0.1 ml/10 g body weight. Intracisternal and 
intrathecal injections were administered in a volume of 5 µl, and intraplantar injection was in a 
volume of 20 µl. 
 
Behavioral experiments 
In the first series of experiments, individual mice underwent either allodynia (mechanical and 
cold allodynia) tests or hyperalgesia (mechanical and thermal hyperalgesia) tests. For habituation 
to experimental procedures, the mice underwent scheduled behavioral test(s) for 3 days before 
bortezomib administration. 
Mechanical allodynia was evaluated using a fine von Frey filament of a bending force of 0.69 
mN (North Coast Medical Inc., Morgan Hill, CA, USA) (20). The mice were placed individually 
in an acrylic cage (11 cm × 18 cm × 15 cm) with a wire mesh bottom. After an acclimation period 
of at least 30 min, the von Frey filament was pressed perpendicularly against the central part of 
the plantar hind paw of freely-moving mice and was held there for 1–3 s by slight buckling. 
Responses to the stimulus were scored as follows: 0, no reaction; 1, lifting of the hind paw; 2, 
licking and flinching of the hind paw. Stimulations were applied to each hind paw three times at 
intervals of several seconds, and the allodynia score (the total score of six tests) was expressed as 
the percentage of a maximum score of 12. 
Mechanical hyperalgesia was evaluated by the tail-pressure method, using an 
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Analgesy-Meter apparatus (Ugo Basile, Milan, Italy). The mice were held by the hand, pressure 
was applied to the base of the tail by a wedge-shaped pusher at a loading rate of 32 g/s with a 
cut-off of 250 g, and the weight of stimulation eliciting either tail withdrawal or a struggling 
response was determined as a nociceptive threshold (21). 
Thermal nociception was evaluated by the radiant heat method, using a tail-flick apparatus 
Type 7360 (Ugo Basile). The mice were held by the hands, radiant heat was applied to the plantar 
hind paws from underneath, and the latency of paw withdrawal was automatically determined 
(22). The intensity of radiant heat was adjusted to elicit a response around 13 s in normal mice. 
Stimulations were applied twice to each hind paw at intervals of more than 10 min, and the 
average of four tests was considered nociceptive latency. 
For the evaluation of cold allodynia, the plantar hind paw was stimulated with acetone (23). 
The mice were placed individually in an acrylic cage (11 cm × 18 cm × 15 cm) with a wire mesh 
bottom. After an acclimation period of at least 30 min, a droplet of acetone was applied to the 
plantar skin of freely-moving mice. Response scoring was performed similarly to that of 
mechanical allodynia, although responses were observed between 3 and 20 s after application. 
Because paw lifting is generally observed immediately (within a few seconds) after acetone 
stimulation in healthy mice, this behavior was ignored. Stimulations were applied twice to each 
hind paw at intervals of more than 20 s, and the cold allodynia score (the total score of four tests) 
was expressed as the percentage of a maximum score of 8. 
 
Electrophysiological recording 
The saphenous nerve activity was recorded on day 12 after bortezomib injection. Mice were 
anesthetized with sodium pentobarbital (80 mg/kg, intraperitoneal; Sigma-Aldrich). The animals 
were turned on their back, and the skin and muscles were excised to expose the saphenous nerve. 
Extracellular recording of nerve activity was performed using bipolar electrodes made of silver 
wire (Unique Medical Co., Ltd., Tokyo) and an AC bioelectric amplifier (AB651; Nihon Kohden, 
Tokyo) with a band-pass filter (high-cut filter, 3 kHz; low-cut filter, 150 Hz). Thirty minutes after 
the beginning of the recording, spontaneous firing was measured for 10 min, followed by firing 
induced by punctate stimulations with the von Frey filament (0.69 mN strength; for 10 s) and 
acetone application (10 µl/site). Compound action potentials were analyzed with a spike height 
histogram software (PowerLab/8s, AD Instruments Pty, Castle Hill, Australia).  
 
Measurement of monoamine contents 
Monoamine contents were determined as previously reported (19). On day 12 after 
bortezomib injection, the spinal cord was excised after the behavioral examination and 
homogenized in 0.2 M perchloric acid containing 100 mM ethylenediaminetetraacetic acid 
disodium and 100 ng 3,4-dihydroxybenzylamine hydrobromide (Sigma-Aldrich) as an internal 
standard. Homogenates were centrifuged at 20,000 ×g for 10 min at 4°C. The supernatant was 
filtered through a 0.45-µm membrane filter, and the pH was adjusted to 3.0 with sodium acetate. 
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Monoamines were determined using a high-performance liquid chromatography with an 
Eicompak SC-50ODS column (3.0 mm inner diameter × 150 mm, Eicom, Kyoto) and an 
electrochemical detector (HTEC-500, Eicom), which was set at a potential +750 mV against an 
Ag/AgCl reference electrode. The mobile phase consisted of 0.1 M acetate–citrate buffer (pH 3.5), 
190 mg/l sodium 1-octanesulfonate, 5 mg/l ethylenediaminetetraacetic acid disodium, and 17% 
methanol. The flow rate was maintained at 0.5 ml/min. 
 
Western blotting 
Twelve days after bortezomib injection, the mice were euthanized by transcardiac perfusion 
of phosphate-buffered saline (PBS) under pentobarbital anesthesia (80 mg/kg, intraperitoneal). 
The pons, medulla oblongata, spinal cord (L4 and L5 levels), and plantar skin were excised, and 
proteins were extracted from the tissue samples with a lysis buffer (20 mM Tris HCl pH 7.5, 137 
mM NaCl, 1% NP-40, 10% glycerol, 1 mM phenylmethyl sulfonyl fluoride, 10 μg/ml aprotinin, 
and 1 μg/ml leupeptin). The extracted proteins (20 µg) were separated by electrophoresis using a 
10% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene difluoride 
membranes. After blocking with a 5% skim milk solution for 1 h, the membranes were incubated 
with rabbit anti-2-1 subunit antibody (Alomone Labs, Jerusalem, Israel) or rabbit 
anti-glyceraldehyde 3-phosphate dehydrogenase antibody (Imgenex Co., San Diego, CA, USA) 
overnight at 4°C. After several washes, the membranes were incubated with horseradish 
peroxidase-conjugated anti-rabbit immunoglobulin G antibody (GE Healthcare, Buckinghamshire, 
UK) for 90 min at room temperature and then treated with chemiluminescence reagents (GE 
Healthcare). Chemiluminescent signals were detected using using a normal radiography and 
analyzed with an NIH Image software. The data were normalized to the level of glyceraldehyde 
3-phosphate dehydrogenase. 
 
Data processing 
Data were represented as mean ± standard error of the mean (SEM). Statistical significance 
was analyzed using one-way analysis of variance (ANOVA) or two-way repeated measures 
ANOVA followed by post-hoc Tukey's honestly significant difference test, except for 
electrophysiological data that was analyzed with Student's t-test. A p value <0.05 was considered 
statistically significant. 
 
 
Results 
Mechanical hypersensitivities, thermal hyperalgesia, and cold allodynia after bortezomib 
administration 
Single intravenous injections of bortezomib (0.03–0.3 mg/kg) dose-dependently induced 
mechanical allodynia (Fig. 1A). A single injection of bortezomib (0.3 mg/kg) also induced 
mechanical hyperalgesia (Fig. 1B). These effects started to appear 3 days after bortezomib 
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administration, peaked on day 12, and almost disappeared by day 24 (Fig. 1A and B). On the 
other hand, bortezomib (0.3 mg/kg) neither induced cold allodynia nor affected nociceptive 
responses to heat stimulation (Fig. 1C and D). 
 
Effects of bortezomib on saphenous nerve activity 
The spontaneous and evoked activities of the saphenous nerve were compared between 
bortezomib- and vehicle-administered mice on day 12 after administration. Bortezomib had a 
tendency to increase the spontaneous activity of the saphenous nerve (Fig. 2). The responses to 
punctate stimulation with a fine von Frey filament (0.69 mN strength) were significantly 
increased after bortezomib administration, whereas the responses to acetone stimulation were not 
significantly increased (Fig. 2). 
 
Effects of gabapentin on bortezomib-induced mechanical allodynia 
The effects of gabapentin on bortezomib-induced mechanical allodynia were examined on 
day 12 after bortezomib (0.3 mg/kg) administration. Oral administration of gabapentin (30 and 
100 mg/kg) produced a significant dose-dependent inhibition of mechanical allodynia. The 
effects peaked 1 h after gabapentin administration and almost disappeared after 6 h (Fig. 3A). 
Intracisternal injections of gabapentin (30 and 100 µg/site) also produced a significant, 
dose-dependent inhibition of mechanical allodynia. The effects peaked 30 min after injection and 
almost disappeared after 2 h (Fig. 3B). Intrathecal injections of gabapentin (30 and 100 µg/site) 
had a tendency to reduce mechanical allodynia but this apparent difference was not statistically 
significant (Fig. 3C). Intraplantar injections of gabapentin (30 and 100 µg/site) did not affect 
mechanical allodynia for 3 h after administration (Fig. 3 D). 
 
Effects of intrathecal neurotoxins on the antiallodynic action of gabapentin 
Three days after intrathecal injection of the catecholaminergic neurotoxin 6-OHDA (Fig. 4A), 
the noradrenaline content in the spinal cord was markedly and significantly reduced in these mice 
than in vehicle-treated mice (VH2-treated groups), although dopamine and 5-hydroxytryptamine 
contents were unaffected (Fig. 4B). Treatment with 6-OHDA did not affect mechanical allodynia 
on day 12 after bortezomib (0.3 mg/kg) administration; allodynia scores before gabapentin 
administration were 1.11 ± 0.09 and 1.25 ± 0.06 (n = 6 each) in the gabapentin + VH2 and 
gabapentin + 6-OHDA groups, respectively. In mice treated with 6-OHDA, gabapentin (100 
mg/kg) inhibited mechanical allodynia, but the effects were significantly reduced compared to the 
gabapentin + VH2 group (Fig. 4C). 
Three days after intrathecal injection of the serotonergic neurotoxin 5,7-DHT (Fig. 4D), the 
5-hydroxytrytamine content in the spinal cord was markedly and significantly reduced in these 
mice than in vehicle-treated mice (VH3-treated groups), although noradrenaline and dopamine 
contents were unaffected (Fig. 4E). Treatment with 5,7-DHT did not affect mechanical allodynia 
on day 12 after bortezomib administration; allodynia scores before gabapentin administration 
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were 1.19 ± 0.05 and 1.28 ± 0.04 (n = 6 each) in gabapentin + VH3 and gabapentin + 5.7-DHT 
groups, respectively. Pretreatment with 5,7-DHT did not affect the antiallodynic action of 
gabapentin (100 mg/kg) (Fig. 4F). 
 
Effects of bortezomib on the expression of the calcium channel 2-1 subunit in the skin, spinal 
cord, medulla oblongata, and pons 
The calcium channel 2-1 subunit was substantially expressed in the plantar skin, spinal 
cord, medulla oblongata, and pons. Single intravenous injection of bortezomib (0.3 mg/kg) did 
not affect the expression level of the 2-1 subunit in these regions examined 12 days after 
bortezomib administration (Fig. 5). 
 
 
DISCUSSION 
Patients treated with bortezomib report pain after light touch, and burning pain worsens 
during walking and manual activities such as knitting or typing (5). Thus, bortezomib induces 
mechanical allodynia and/or mechanical hyperalgesia in humans. In the present study, a single 
intravenous injection of bortezomib induced mechanical allodynia and mechanical hyperalgesia 
in mice. These results are consistent with those observed by other groups, which reported the 
mechanical hyperalgesic effects of bortezomib in rats (9–11). We also observed on the day when 
mechanical allodynia peaked that bortezomib (0.3 mg/kg) significantly increased the activity of 
the saphenous nerve after punctate stimulation with a fine von Frey filament. These results 
suggest that bortezomib-induced mechanical allodynia is mediated by the increased reactivity of 
primary afferents to tactile stimulation.  
In patients with myeloma, bortezomib increases heat pain threshold, suggesting thermal 
hypoalgesia (5). Similarly, bortezomib (a cumulative dose of 12 mg/kg) has been shown to induce 
thermal hypoalgesia in mice (7). However, in the present study, bortezomib (0.3 mg/kg) did not 
affect heat nociceptive responses in mice, which is consistent with another study in rats using a 
cumulative dose of 4.8 mg/kg bortezomib (10). Thus, it is suggested that thermal hypoalgesia 
might occur when using higher doses of bortezomib and that C-fiber function is not inhibited 
under our experimental conditions. 
Bortezomib (0.3 mg/kg) did not induce cold allodynia in the acetone test and did not affect 
the reactivity of primary afferents to acetone stimulation. Regarding cold sensitivity, repeated 
administration of bortezomib (0.2 mg/kg per day, a total of 1 mg/kg) was reported to cause 
long-lasting cold allodynia in rats (11). However, repeated administration of bortezomib (0.8 
mg/kg per day, a total of 6.4 mg/kg) was reported not to affect the temperature of cold response 
threshold (9.4–10.5°C) in mice (24). The reason for the discrepancies is unclear except for 
species differences. In patients with myeloma, bortezomib does not affect the temperature of cool 
detection threshold (approximately 28°C), but it increases pain threshold to skin cooling from 
3°C (healthy subjects) to approximately 10°C (5). Thus, we do not exclude the possibility that 
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bortezomib causes cold hyperalgesia, for example, an increase in pain-like behavioral responses 
to ice-cold stimulation in mice. 
Treatment with 6-OHDA or 5,7-DHT that selectively decreased the contents of 
noradrenaline or serotonin, respectively, in the spinal cord did not affect bortezomib-induced 
allodynia. Therefore, it is suggested that bortezomib-induced allodynia is not due to changes in 
the function of the descending noradrenergic or serotonergic system. 
Bortezomib-induced mechanical allodynia was markedly inhibited after systemic 
administration of gabapentin. Gabapentin has been shown to inhibit mechanical allodynia 
induced by other chemotherapeutic agents, such as paclitaxel (13,16) and oxaliplatin (13,18). In 
the present study, bortezomib-induced mechanical allodynia was markedly inhibited by 
intracisternal injections of gabapentin, whereas gabapentin intrathecal injections were less 
effective, and intraplantar injections had no effect on the allodynia. These results suggest that 
gabapentin inhibits bortezomib-induced allodynia mainly through its supraspinal action, and that 
its actions on primary sensory neurons and spinal neurons are minimal in bortezomib-treated 
mice. In contrast to bortezomib-induced mechanical allodynia, intrathecal injections of 
gabapentin have been shown to markedly inhibit paclitaxel-induced mechanical allodynia (13). 
Thus, the mechanisms of the antiallodynic action of gabapentin seem to be different, depending 
on the type of chemotherapeutic agents. 
The N-type voltage-dependent calcium channel in the primary sensory neuron has been 
claimed to be involved in the antinociceptive effect of intrathecal gabapentin (25). The α2δ-1 
subunit of the voltage-dependent calcium channel has been shown to be a key gabapentin binding 
site mediating its antiallodynic action (26). Paclitaxel increases the expression of the α2δ-1 
subunit in the spinal dorsal horn and dorsal root ganglia (13,16), and oxaliplatin increases the 
expression of the α2δ-1 subunit in the dorsal root ganglia (13). The α2δ-1 subunit is mainly 
present in small-sized dorsal root ganglion neurons, and paclitaxel increases the number of 
medium/large-sized dorsal root ganglion neurons expressing the α2δ-1 subunit (16). Paclitaxel 
decreases thresholds for activation of Aδ- and Aβ-fibers (mainly the axons of medium/large-sized 
dorsal root ganglion neurons) (16). These findings taken together suggest that the up-regulation 
of the α2δ-1 subunit in the A-fiber sensory neurons is associated with the antiallodynic effect of 
gabapentin mediated by its action on primary sensory neurons. However, in the present study, 
western blot analyses showed that bortezomib did not affect the expression level of the α2δ-1 
subunit in the spinal cord and plantar skin. Thus, it is suggested that bortezomib does not 
up-regulate the α2δ-1 subunit in the A-fiber sensory neurons, which may be a reason for the 
minimal or no antiallodynic effects after intrathecal and intraplantar gabapentin injections in 
bortezomib-treated mice. 
The antiallodynic effects observed after systemic administration of gabapentin were partially 
but significantly reduced by noradrenaline depletion but not by serotonin depletion in the spinal 
cord. The reduction of antiallodynic activity of systemic administration of gabapentin was not 
due to changes in allodynia after noradrenaline depletion, because intrathecal treatment with 
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6-OHDA did not affect bortezomib-induced allodynia. Thus, it is suggested that the descending 
noradrenergic system is involved in the antiallodynic action of gabapentin in bortezomib-treated 
mice. This idea is consistent with the result that an intracisternal injection of gabapentin inhibited 
bortezomib-induced allodynia. In a mouse model of surgery-induced peripheral neuropathy, the 
antiallodynic effects of gabapentin after systemic and intracerebroventricular injections were 
reduced by intracisternal pretreatment with 6-OHDA (27). In the locus coeruleus, a nucleus of 
origin of the descending noradrenergic system (28), γ-aminobutyric acid (GABA) released from 
GABAergic neurons were shown to regulate the activity of descending noradrenergic neurons 
(29,30). Moreover, the calcium channel 2-1 subunit is highly expressed in the locus coeruleus 
(31), and it has been shown that gabapentin can activate descending noradrenergic neurons 
through a disinhibition of GABAergic neurons in the locus coeruleus (32). Taken together, these 
findings suggest that the antiallodynic effects of gabapentin in bortezomib-treated mice result 
from the activation of descending noradrenergic neurons via the disinhibition of GABAergic 
neurons in the locus coeruleus. However, bortezomib did not affect the expression level of the 
calcium channel 2-1 subunit in the pons that includes the locus coeruleus. Thus, increasing the 
expression of the 2-1 subunit does not seem necessary for the descending noradrenergic 
system-mediated antiallodynic action of gabapentin. Moreover, it has been shown that gabapentin 
can inhibit the release of excitatory amino acids in the spinal dorsal horn and regulate 
glutamatergic synaptic transmission in conditions where the 2-1 subunit expression level is 
normal (33,34). Thus, it is possible that presynaptic mechanisms are also responsible for the 
antiallodynic effects of gabapentin. 
In summary, bortezomib induced mechanical allodynia and hyperalgesia, but not thermal 
hypoalgesia/hyperalgesia and cold allodynia in mice. Gabapentin attenuated bortezomib-induced 
mechanical allodynia most likely through supraspinal activation of the descending noradrenergic 
system. Gabapentin may be effective for the management of mechanical allodynia and 
hyperalgesia in patients treated with bortezomib. 
 
 
Conflict of interest statement 
The authors declare no conflicts of interest. 
 
Acknowledgments 
This research was supported by Takeda Science Foundation 2009. 
 
  
15 
 
References 
1. Barr P, Fisher R, Friedberg J. The role of bortezomib in the treatment of lymphoma. Cancer 
Invest. 2007;25:766–775.  
2. Curran MP, McKeage K. Bortezomib: a review of its use in patients with multiple myeloma. 
Drugs. 2009;69:859–888. 
3. Kane RC, Dagher R, Farrell A, Ko CW, Sridhara R, Justice R, et al. Bortezomib for the 
treatment of mantle cell lymphoma. Clin Cancer Res. 2007;13:5291–5294. 
4. Badros A, Goloubeva O, Dalal JS, Can I, Thompson J, Rapoport AP, et al. Neurotoxicity of 
bortezomib therapy in multiple myeloma: a single-center experience and review of the 
literature. Cancer. 2007;110:1042–1049. 
5. Cata JP, Weng HR, Burton AW, Villareal H, Giralt S, Dougherty PM. Quantitative sensory 
findings in patients with bortezomib-induced pain. J Pain. 2007;8:296–306. 
6. Richardson PG, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, et al. 
Reversibility of symptomatic peripheral neuropathy with bortezomib in the phase III APEX 
trial in relapsed multiple myeloma: impact of a dose-modification guideline. Br J Haematol. 
2009;144:895–903. 
7. Bruna J, Udina E, Alé A, Vilches JJ, Vynckier A, Monbaliu J, et al. Neurophysiological, 
histological and immunohistochemical characterization of bortezomib-induced neuropathy 
in mice. Exp Neurol. 2010;223:599–608.  
8. Cavaletti G, Gilardini A, Canta A, Rigamonti L, Rodriguez-Menendez V, Ceresa C, et al. 
Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study 
in the rat. Exp Neurol. 2007;204:317–325. 
9. Janes K, Doyle T, Bryant L, Esposito E, Cuzzocrea S, Ryerse J, et al. Bioenergetic deficits 
in peripheral nerve sensory axons during chemotherapy-induced neuropathic pain resulting 
from peroxynitrite-mediated post-translational nitration of mitochondrial superoxide 
dismutase. Pain. 2013;154:2432–2440. 
10. Meregalli C, Canta A, Carozzi VA, Chiorazzi A, Oggioni N, Gilardini A, et al. 
Bortezomib-induced painful neuropathy in rats: a behavioral, neurophysiological and 
pathological study in rats. Eur J Pain. 2010;14:343–350.  
11. Zheng H, Xiao WH, Bennett GJ. Mitotoxicity and bortezomib-induced chronic painful 
peripheral neuropathy. Exp Neurol 2012;238:225–234. 
12. Backonja M, Glanzman RL. Gabapentin dosing for neuropathic pain: evidence from 
randomized, placebo-controlled clinical trials. Clin Ther. 2003;25:81–104. 
13. Gauchan P, Andoh T, Ikeda K, Fujita M, Sasaki A, Kato A, et al. Mechanical allodynia 
induced by paclitaxel, oxaliplatin and vincristine: different effectiveness of gabapentin and 
different expression of voltage-dependent calcium channel alpha2delta-1 subunit. Biol 
Pharm Bull. 2009a;32:732–734. 
14. Luo ZD, Calcutt NA, Higuera ES, Valder CR, Song YH, Svensson CI, et al. Injury 
type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain 
16 
 
models correlates with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 
2002;303:1199–1205. 
15. Lynch JJ III, Wade CL, Zhong CM, Mikusa JP, Honore P. Attenuation of mechanical 
allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. 
Pain. 2004;110:56–63. 
16. Matsumoto M, Inoue M, Hald A, Xie W, Ueda H. Inhibition of paclitaxel-induced A-fiber 
hypersensitization by gabapentin. J Pharmacol Exp Ther. 2006;318:735–740. 
17. Xiao W, Boroujerdi A, Bennett GJ, Luo ZD. Chemotherapy-evoked painful peripheral 
neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta 
type-1 calcium channel subunit. Neuroscience. 2007;144:714–720. 
18. Ling B, Authier N, Balayssac D, Eschalier A, Coudore F. Behavioral and pharmacological 
description of oxaliplatin-induced painful neuropathy in rat. Pain. 2007;128:225–234. 
19. Gotoh Y, Omori Y, Andoh T, Kuraishi Y. Tonic inhibition of allergic itch signaling by the 
descending noradrenergic system in mice. J Pharmacol Sci. 2011;115:417–420. 
20. Fujita M, Andoh T, Saiki I, Kuraishi Y. Involvement of endothelin and ETA endothelin 
receptor in mechanical allodynia in mice given orthotopic melanoma inoculation. J 
Pharmacol Sci. 2008;106:257–263. 
21. Andoh T, Yageta Y, Konno M, Yamaguchi-Miyamoto T, Takahata H, Nojima H, et al. 
Evidence for separate involvement of different µ-opioid receptor subtypes in itch and 
analgesia induced by supraspinal action of opioids. J Pharmacol Sci. 2008;106:667–670. 
22. Sasamura T, Nakamura S, Iida Y, Fujii H, Murata J, Saiki I, Nojima H, Kuraishi Y. 
Morphine analgesia suppresses tumor growth and metastasis in a mouse model of cancer 
pain produced by orthotopic tumor inoculation. Eur J Pharmacol. 2002;441:185–191. 
23. Gauchan P, Andoh T, Kato A, Kuraishi Y. Involvement of increased expression of transient 
receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett. 
2009;458:93–95. 
24. Carozzi VA, Renn CL, Bardini M, Fazio G, Chiorazzi A, Meregalli C, Oggioni N, Shanks K, 
Quartu M, Serra MP, Sala B, Cavaletti G, Dorsey SG. Bortezomib-induced painful 
peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic 
study in the mouse. PLoS One. 2013;8:e72995. 
25. Cheng JK, Chiou LC. Mechanisms of the antinociceptive action of gabapentin. J Pharmacol 
Sci 2006;100:471–486. 
26. Field MJ, Cox PJ, Stott E, Melrose H, Offord J, Su TZ, et al. Identification of the 2--1 
subunit of voltage-dependent calcium channels as a molecular target for pain mediating the 
analgesic actions of pregabalin. Proc Natl Acad Sci USA. 2006;103:17537–17542. 
27. Tanabe M, Takasu K, Takeuchi Y, Ono H. Pain relief by gabapentin and pregabalin via 
supraspinal mechanisms after peripheral nerve injury. J Neurosci Res. 2008;86:3258–3264. 
28. Foote SL, Bloom FE, Aston-Jones G. Nucleus locus ceruleus: new evidence of anatomical 
and physiological specificity. Physiol Rev. 1983;63:844–914.  
17 
 
29. Pan YZ, Li DP, Chen SR, Pan HL. Activation of -opioid receptors excites spinally 
projecting locus coeruleus neurons through inhibition of GABAergic inputs. J Neurophysiol. 
2002;88:2675–2683. 
30. Pan YZ, Li DP, Chen SR, Pan HL. Activation of µ-opioid receptors excites a population of 
locus coeruleus-spinal neurons through presynaptic disinhibition. Brain Res. 
2004;997:67–78. 
31. Cole RL, Lechner SM, Williams ME, Prodanovich P, Bleicher L, Varney MA, et al. 
Differential distribution of voltage-gated calcium channel alpha-2 delta (2) subunit 
mRNA-containing cells in the rat central nervous system and the dorsal root ganglia. J 
Comp Neurol. 2005;491:246–269. 
32. Tanabe M, Takasu K, Kasuya N, Shimizu S, Honda M, Ono H. Role of descending 
noradrenergic system and spinal 2-adrenergic receptors in the effects of gabapentin on 
thermal and mechanical nociception after partial nerve injury in the mouse. Br J Pharmacol. 
2005;144:703–714. 
33. Feng Y, Cui M, Willis WD. Gabapentin markedly reduces acetic acid-induced visceral 
nociception. Anesthesiology. 2003;98:729–733. 
34. Shimoyama M, Shimoyama N, Hori Y. Gabapentin affects glutamatergic excitatory 
neurotransmission in the rat dorsal horn. Pain. 2000;85:405–414. 
 
  
18 
 
FIGURE LEGENDS  
 
Fig. 1. Effects of bortezomib on responses to innocuous and noxious stimuli. Mice were injected 
intravenously with bortezomib or vehicle on day 0. (A) Mechanical allodynia was tested with a 
von Frey filament of 0.69 mN strength. Main effect of treatment, F3,240 = 11.915, P <0.001; 
interaction between treatment and time, F36,240 = 3.337, P <0.001 (two-way repeated measures 
ANOVA). (B) Mechanical nociception was assessed using the tail-pressure method. Main effect 
of treatment, F1,120 = 34.583, P <0.001; interaction between treatment and time, F12,120 = 3.827, P 
<0.001 (two-way repeated measures ANOVA). (C) Cold allodynia was tested using the 
acetone-application method. (D) Thermal nociception of the hind paw was assessed using a 
tail-flick apparatus. Individual mice underwent either allodynia tests (A and C) or hyperalgesia 
tests (B and D). Values are expressed as means ± SEM (n = 6). *P < 0.05 compared with vehicle 
(Tukey's honestly significant difference test).  
 
Fig. 2. Effects of bortezomib on the spontaneous and evoked activity of the saphenous nerve. 
Bortezomib (0.3 mg/kg, n = 5) and vehicle (n = 6) were administered intravenously and the 
activity of the saphenous nerve was recorded using bipolar electrodes on day 12 after 
administration. The receptive field (plantar hind paw) was stimulated with a von Frey filament 
(0.69 mN strength) and acetone. (A) Typical examples. (B) Quantitative comparison of 
compound action potentials. Values are expressed as means and SEM. *P <0.05 (Student's t-test). 
 
Fig. 3. Effects of gabapentin (GBP) on bortezomib-induced mechanical allodynia. GBP or 
vehicle was administered on day 12 after intravenous injection of bortezomib (0.3 mg/kg). (A) 
Oral administration of gabapentin (30 and 100 mg/kg). N = 6 each group. Main effect of 
treatment, F2,90 = 46.521, P <0.001; interaction between treatment and time, F12,90 = 9.994, P 
<0.001 (two-way repeated measures ANOVA). (B) Intracisternal (i.c.) injection of gabapentin (30 
and 100 µg/site). N = 5, 5, and 4 in vehicle, 30, and 100 µg/site groups, respectively. Main effect 
of treatment, F2,44 = 13.278, P = 0.001; interaction between treatment and time, F8,44 = 4.622, P 
<0.001 (two-way repeated measures ANOVA). (C) Intrathecal (i.t.) injection of gabapentin (30 
and 100 µg/site). N = 6 for each group. (D) Intraplantar (i.pl.) injection of gabapentin (30 and 100 
µg/site). N = 6 for each group. Values are expressed as means ± SEM. *P< 0.05 compared with 
vehicle (Tukey's honestly significant difference test). 
 
Fig. 4. Effects of intrathecal neurotoxins on the levels of monoamines in the spinal cord and the 
inhibitory action of gabapentin (GBP) on bortezomib-induced mechanical allodynia. Bortezomib 
(0.3 mg/kg) was injected intravenously, and 12 days later, gabapentin (100 mg/kg) and vehicle 
(VH1) were administered orally. 6-Hydroxydopamine hydrochloride (6-OHDA, 20 μg/site), 
5,7-dihydroxytryptamine creatinine sulfate (5,7-DHT, 20 μg/site), vehicle for 6-OHDA (VH2), 
and vehicle for 5,7-DHT (VH3) were injected intrathecally 3 days before GBP administration. 
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Mechanical allodynia was examined as described in the Fig. 1 legend. (A) Schedule of 6-OHDA 
experiment. (B) The effects of 6-OHDA on the levels of noradrenaline (NA), dopamine (DA) and 
5-hydroxytryptamine (5-HT) in the spinal cord. Effect on the NA level, F2,15 = 38.905, P <0.001 
(one-way ANOVA). (C) Effects of 6-OHDA on the antiallodynic action of GBP. Main effect of 
treatment, F2,90 = 33.339, P <0.001; interaction between treatment and time, F12,90 = 7.200, P 
<0.001 (two-way repeated measures ANOVA). (D) Schedule of 5,7-DHT experiment. (E) Effects 
of 5,7-DHT on the levels of monoamines in the spinal cord. Effect on 5-HT level, F2,15 = 14.806, 
P <0.001 (one-way ANOVA). (F) Effect of 5,7-DHT on the antiallodynic action of GBP. Main 
effect of treatment, F2,90 = 56.580, P <0.001; interaction between treatment and time, F12,90 = 
13.004, P <0.001 (two-way repeated measures ANOVA). Values are expressed as means ± SEM 
(n = 6). *P<0.05 compared to VH1+VH2 or VH1+VH3, #p <0.05 compared to GBP+VH2 or 
GBP+VH3 (Tukey's honestly significant difference test). 
 
Fig. 5. Effects of bortezomib on the levels of the calcium channel α2δ-1 subunit in the skin and 
central nervous system regions. The levels of α2δ-1 subunit in the plantar skin, spinal cord, 
medulla oblongata, and pons were assessed 12 days after intravenous administration of 
bortezomib (BTZ, 0.3 mg/kg) or vehicle (VH), using western blotting analyses. Upper panel, 
typical western blot bands of α2δ-1 subunit and glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH). Lower panel, the expression level of α2δ-1 subunit normalized to that of GAPDH. 
Values are expressed as means and SEM (n = 6). 
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Fig. 3
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Abstract 
Oxaliplatin, a key chemotherapeutic drug, frequently causes peripheral neuropathy accompanied 
by pain and allodynia. A few recent clinical studies showed that a traditional herbal formulation 
goshajinkigan (GJG) prevents oxaliplatin-induced neuropathy. In this study, we examined the 
mechanisms underlying acute antiallodynic activity of GJG in mice with oxaliplatin-induced 
neuropathy. A single intraperitoneal injection of oxaliplatin (3 mg/kg) induced mechanical 
allodynia, which peaked at day 10 after injection and subsided almost completely by day 18. On 
day 10 after oxaliplatin injection, oral administration of GJG (0.3 and 1.0 g/kg, but not 0.1 g/kg) 
inhibited established mechanical allodynia after oxaliplatin administration. The inhibitory effect 
peaked 30 min after GJG administration and subsided by 2 h. The antiallodynic activity of GJG 
was inhibited by intrathecal pretreatment with the catecholaminergic neurotoxin 
6-hydroxydopamine (20 μg/site) and the serotonergic neurotoxin 5,7-dihydroxytryptamine (60 
μg/site). Administration of GJG (1.0 g/kg) to oxaliplatin-treated mice showed no effect on the 
levels of noradrenaline, serotonin, 3-methoxy-4-hydroxyphenylglycol (a noradrenaline 
metabolite), and 5-hydroxyindoleacetic acid (a serotonin metabolite). These results suggest that 
the descending noradrenergic and serotonergic systems are involved in GJG-mediated inhibition 
of oxaliplatin-induced mechanical allodynia. 
 
Keywords  oxaliplatin, mechanical allodynia, goshajinkigan, descending noradrenergic system, 
descending serotonergic system 
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Introduction 
Oxaliplatin is widely used for the treatment of colorectal cancer. However, oxaliplatin frequently 
causes severe acute and chronic peripheral neuropathy, which is usually accompanied by pain, 
dysesthesia (especially cold dysesthesia), or paresthesia.1) Peripheral neuropathy is the major 
limiting factor for oxaliplatin therapy. The mechanisms underlying oxaliplatin-induced peripheral 
neuropathy are not completely understood; however, oxalate, a metabolite of oxaliplatin, is 
involved in peripheral neurotoxicity, especially cold dysesthesia.2,3) Several drugs, including 
calcium gluconate/magnesium sulfate, glutathione, carbamazepine, gabapentin, amifostine, 
acetyl-L-carnitine, and α-lipoic acid, have been used to manage oxaliplatin-induced peripheral 
neuropathy.4) Although these drugs are effective against mild neuropathy, oxaliplatin-induced 
peripheral neuropathy is still difficult to treat.4)  
Goshajinkigan (GJG) is a traditional formulation consisting of Rehmanniae Radix, 
Achyranthis Radix, Corni Fructus, Dioscoreae Rhizoma, Plantaginis Semen, Alismatis Rhizoma, 
Poria, Moutan Cortex, Cinnamoni Cortex and Processi Aconiti Radix. GJG is used for the 
treatment of several neurological symptoms including pain and dysesthesia. Administration of 
GJG during oxaliplatin therapy prevents peripheral neuropathy in patients with colorectal 
cancer.5,6) In animal studies, however, repeated administration of GJG does not prevent 
oxaliplatin-induced mechanical allodynia and axonal degeneration in the sciatic nerve, but single 
administration of GJG inhibits established mechanical allodynia.7) In addition, single 
administration of GJG exerts antinociception in naïve mice and inhibits mechanical hyperalgesia 
in diabetic mice.8) These findings taken together suggest that GJG exerts acute antiallodynic 
effect without preventing the development of allodynia. Regarding analgesic mechanisms, GJG 
suppresses mechanical hyperalgesia in diabetic mice, which is inhibited by systemic 
administration of methysergide, a serotonin antagonist, and yohimbine, an α2-adrenoceptor 
antagonist.8) These findings raise the possibility that GJG facilitates the function of the 
descending pain inhibitory serotonergic and noradrenergic systems or stimulates serotonergic and 
adrenergic receptors. Therefore, in this study, we investigated whether the acute antiallodynic 
activity of GJG in oxaliplatin-treated mice is mediated by the descending serotonergic and/or 
noradrenergic systems. 
 
 
Materials and Methods 
Animals: We used male C57BL/6NCr mice (Japan SLC, Shizuoka, Japan). All animals were 6 
weeks old at the start of the experiments. They were housed in a room with controlled 
temperature (21–23°C) humidity (45%–65%), and light (lights on from 7:00 AM to 7:00 PM). 
Food and water were freely available. Experiments were performed after obtaining approval from 
the animal care committee of the University of Toyama, and according to the guidelines for 
investigations of experimental pain in animals published by the International Association for the 
Study of Pain. 
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Drugs: Oxaliplatin (Sigma, St. Louis, MO) was dissolved in 5% glucose. Oxaliplatin (3 mg/kg) 
was administered intraperitoneally; the dose was selected from a published report and according 
to the recommended clinical dose of this drug.9) The dried extract of GJG (Lot. No. 2080107010, 
2009) was obtained from Tsumura & Co., Ltd. (Tokyo, Japan). The dried GJG extract was 
dissolved in 5% gum arabic and was administered orally on day 10 after oxaliplatin injection. 
6-Hydroxydopamine hydrochloride (6-OHDA, Sigma) and 5,7-dihydroxytryptamine 
creatinine sulfate (5,7-DHT, Sigma) were dissolved in physiological saline containing 0.1% 
ascorbic acid. Mice received an intrathecal injection of 6-OHDA (20 μg/mouse) or 5,7-DHT (60 
μg/mouse) 3 days before GJG administration; desipramine hydrochloride (25 mg/kg, Sigma) was 
injected intraperitoneally 30 min before the 5,7-DHT injection to block the uptake into the 
noradrenergic nerve terminals.3,10) 
 
Behavioral experiments: Mechanical allodynia in the hind paw was evaluated using a fine von 
Frey filament (North Coast Medical Inc., Morgan Hill, CA). After an acclimation period of at 
least 30 min, a von Frey filament with a bending force of 1.6 mN was applied perpendicularly 
against the central part of the plantar hind paw and was held for 1–3 s with it slightly bent. 
Responses to the stimuli were scored as follows: no reaction, 0; lifting of the hind paw, 1; and 
licking and flinching of the hind paw, 2. A stimulus of the same intensity was applied 6 times to 
the hind paw at intervals of several seconds and the average response score was expressed as the 
percentage of the maximum score 2. 
 
Measurement of the levels of monoamines and metabolites: The levels of monoamines and 
their metabolites in the spinal cord were determined according to a previously described 
method.10) Briefly, the spinal cord was isolated from the mice after the behavioral test on day 10 
after oxaliplatin administration. Immediately after isolation, the tissues were homogenized in 0.2 
M perchloric acid containing 100 mM disodium ethylenediaminetetraacetate and 100 ng of 
isoproterenol (Sigma) as an internal standard. The homogenate was centrifuged at 20,000g for 10 
min at 4°C, and the supernatant was filtered through a 0.45-m membrane filter; the pH of the 
supernatant was adjusted to 3 with sodium acetate. The levels of noradrenaline, dopamine, 
serotonin, 3-methoxy-4-hydroxyphenylglycol (MHPG), and 5-hydroxyindoleacetic acid 
(5-HIAA) were determined using high-performance liquid chromatography (HTEC-500; Eicom, 
Kyoto, Japan) with an Eicompak SC-50ODS column (internal diameter 3.0 mm × 150 mm, 
Eicom) and an electrochemical detector. An Ag/AgCl reference electrode was set at a potential of 
+750 mV. The mobile phase consisted of 0.1 M acetate-citrate buffer (pH 3.5), 190 mg/L sodium 
1-octanesulfonate, 5 mg/L disodium ethylenediaminetetraacetate and 17% methanol; the flow rate 
was maintained at 0.5 mL/min. 
 
Statistical analysis: All data are presented as means and standard error of the mean. Statistical 
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significance was analyzed using one-way analysis of variance (ANOVA) followed by Dunnett's 
test or repeated measures ANOVA followed by Tukey's honestly significant difference test. P < 
0.05 was considered statistically significant. The statistical analyses were performed using 
Sigmaplot graphing and statistical software (version 11; Systat Software, Inc., Chicago, IL). 
 
 
Results 
Oxaliplatin-induced mechanical allodynia: A single intraperitoneal injection of oxaliplatin (3 
mg/kg) caused mechanical allodynia, which was apparent on day 4 after injection, peaked on day 
10, and almost subsided by day 18 (Fig. 1). In the subsequent experiments, we examined the 
effects of different agents on oxaliplatin-induced allodynia on day 10. 
 
Effects of GJG on oxaliplatin-induced mechanical allodynia: Oral administration of GJG 
(0.1–1.0 g/kg) on day 10 after oxaliplatin injection showed dose-dependent inhibition of 
mechanical allodynia; significant inhibition of mechanical allodynia was observed after 
administration of 0.3 and 1.0 g/kg of GJG (Fig. 2). The effects of these doses were statistically 
significant at 30 and 60 min after administration and almost subsided by 2 h (Fig. 2). 
 
Effects of neurotoxins on the antiallodynic action of GJG: Experimental schedules are shown 
in Fig. 3A and B. As shown in Fig. 3C, an intrathecal injection of the catecholaminergic 
neurotoxin 6-OHDA (20 μg/site) significantly decreased the noradrenaline level, without 
affecting the levels of dopamine and serotonin (5-hydroxytryptamine), as compared with vehicle 
(VH2-treated groups in Fig. 3C). On the other hand, an intrathecal injection of the serotonergic 
neurotoxin 5,7-DHT (60 μg/site) significantly decreased the level of serotonin in the spinal cord 
but did not affect the levels of noradrenaline and dopamine, as compared with vehicle 
(VH3-treated groups in Fig. 3D). 
Intrathecal treatment with 6-OHDA did not affect mechanical allodynia on day 10 after 
oxaliplatin injection (3 mg/kg); pain-related scores before GJG administration were 1.07 ± 0.07 
and 1.20 ± 0.06 (n = 5 each) in GJG + VH2 and GJG + 6-OHDA groups, respectively. Similarly, 
intrathecal treatment with 5,7-DHT did not affect oxaliplatin-induced mechanical allodynia; 
pain-related scores before GJG administration were 1.03 ± 0.10 and 1.17 ± 0.05 (n = 5 each) in 
GJG + VH3 and GJG + 5,7-DHT groups, respectively. 
Oral administration of GJG (1.0 g/kg) significantly inhibited oxaliplatin-induced mechanical 
allodynia at 30 and 60 min after administration (GJG + VH2 group in Fig. 3E and GJG +VH3 
group in Fig. 3F). In mice pretreated with 6-OHDA, GJG (1.0 g/kg) induced slight inhibition of 
oxaliplatin-induced mechanical allodynia, but the effect was not statistically significant as 
compared with VH1 + VH2 group (Fig. 3E). In mice pretreated with 5,7-DHT, GJG (1.0 g/kg) 
induced slight inhibition of oxaliplatin-induced mechanical allodynia, but the effect was not 
statistically significant as compared with VH1 + VH3 group (Fig. 3F). 
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Effects of GJG on the levels of monoamines and their metabolites in the spinal cord: Oral 
administration of GJG (1.0 g/kg) did not affect the levels of noradrenaline, dopamine, and 
serotonin in the spinal cord (Fig. 3A and B). Further, GJG at the same dose did not affect the 
levels of MHPG (a noradrenaline metabolite) and 5-HIAA (a serotonin metabolite) in the spinal 
cord. The levels of MHPG were 0.074 ± 0.003 (n = 11) and 0.077 ± 0.005 ng/mg tissue (n = 10) 
in the vehicle- and GJG-treated groups, respectively. The levels of 5-HIAA were 0.13 ± 0.01 (n = 
11) and 0.13 ± 0.01 ng/mg tissue (n = 10) in the vehicle- and GJG-treated groups, respectively. 
 
 
Discussion 
An intraperitoneal injection of oxaliplatin (3 mg/kg) to mice induced mechanical allodynia, the 
time course and intensity of which were similar to those previously reported.9) Oral 
administration of GJG inhibited oxaliplatin-induced mechanical allodynia; GJG at doses of 0.3 
and 1.0 g/kg inhibited the allodynia with similar efficacy; however, the lower dose of 0.1 g/kg did 
not inhibit allodynia. GJG (0.3 and 1.0 g/kg) inhibits oxaliplatin-induced mechanical allodynia in 
rats with similar efficacy as that observed in mice.7) GJG increases the mechanical nociceptive 
threshold in naïve mice at oral doses of 0.3 and 1.0 g/kg but not at a dose of 0.1 g/kg.8) Thus, the 
antiallodynic and antinociceptive doses of GJG were similar in rodents. The recommended 
clinical daily dose of GJG granule is 7.5 g, which contains 4.5 g of dried GJG extract. Given that 
the body weight is 60 kg, the dose of the dried GJG extract is 0.075 g/kg. Thus, the antiallodynic 
dose (0.3 g/kg) in mice with oxaliplatin-induced neuropathy was 4 times higher than the 
recommended clinical dose. 
Depletion of noradrenaline and serotonin in the spinal cord did not affect the intensity of 
oxaliplatin-induced allodynia, which suggests that the allodynia is not mediated by changes in the 
functions of the descending noradrenergic and serotonergic systems. The antiallodynic action of 
GJG was inhibited by intrathecal pretreatment with noradrenergic and serotonergic neurotoxins. 
Depletion of either noradrenaline or serotonin in the spinal cord partially but significantly 
reduced the antiallodynic action of GJG, which suggests the involvement of both noradrenergic 
and serotonergic descending systems in the antiallodynic action of GJG. 
Antinociception is produced by microinjections of mesaconitine, an alkaloid contained in 
Processi Aconiti Radix, into three brain regions (nucleus reticularis paragigantocellularis, nucleus 
raphe magnus, and periaqueductal gray) that are involved in the activation of the descending 
noradrenergic and serotonergic systems.11) Thus, it is conceivable that GJG acts on these brain 
regions to activate the descending noradrenergic and serotonergic systems. Morphine that 
activates the descending noradrenergic and serotonergic systems through acting on these regions 
markedly increases 5-HIAA and MHPG in the spinal cord and lower brainstem.12,13) The 
antiallodynic effect of pregabalin is at least partly mediated by the activation of the descending 
noradrenergic system, and pregabalin increases the level of MHPG in the spinal cord.14) Thus, if 
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GJG activates the descending noradrenergic and serotonergic systems, it may increase the levels 
of these monoamine metabolites in the spinal cord. However, in our study, GJG did not increase 
the levels of MHPG and 5-HIAA in the spinal cord in oxaliplatin-treated mice. Thus, the present 
results did not support the idea that GJG facilitates the activity of the descending noradrenergic 
and serotonergic systems. 
Another conceivable mechanism is that GJG inhibits the reuptake of noradrenaline and/or 
serotonin in the spinal cord to enhance their synaptic actions. Although the extracellular 
concentrations of serotonin and noradrenaline are increased by a serotonin–noradrenaline 
reuptake inhibitor with the extracellular concentrations of their metabolites MHPG and 5-HIAA 
unaffected,15) the tissue concentration of 5-HIAA is decreased by the inhibition of serotonin 
reuptake with the tissue concentration of serotonin unaffected, probably because of the decrease 
of serotonin turnover.16) In the present study, however, GJG did not affect the concentration of 
5-HIAA as well as serotonin in the spinal cord. The results did not support the idea that GJG 
inhibits the reuptake of serotonin into the presynaptic terminals of the descending serotonergic 
system. Thus, mechanisms of GJG action on the descending noradrenergic and serotonergic 
systems remain to be clarified. 
GJG suppresses mechanical hyperalgesia in diabetic mice, which is inhibited by systemic 
administration of yohimbine and methysergide.8) Among 10 herbal medicines composing GJG, 
Processi Aconiti Radix has been shown to suppress stress-induced hyperalgesia, which is 
inhibited by systemic administration of idazoxan, an α2-adrenoceptor antagonist, and 
methysergide.17) The similarities between antihyperalgesic mechanisms of GJG and Processi 
Aconiti Radix raise the possibility that Processi Aconiti Radix contributes to the antiallodynic 
activity of GJG. Paeoniflorin suppresses mechanical hyperalgesia in diabetic mice, which is 
inhibited by intrathecal injection of yohimbine.18) Since Moutan Cortex contains paeoniflorin,19) 
Moutan Cortex is also possible to contribute to the antiallodynic activity of GJG. 
In conclusion, GJG inhibits oxaliplatin-induced mechanical allodynia in mice, and the 
descending noradrenergic and serotonergic systems may be involved in the antiallodynic activity 
of GJG. GJG is effective for the treatment of oxaliplatin-induced peripheral neuropathy because 
of the absence of severe adverse effects at the recommended clinical dose.6) 
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Figure legends 
 
Fig. 1  Development of mechanical allodynia after a single injection of oxaliplatin. Mice were 
injected intraperitoneally with oxaliplatin (3 mg/kg) or vehicle (5% glucose) on day 0. 
Mechanical allodynia was examined by punctate stimulation using a von Frey filament (a 
bending force of 1.6 mN). Closed and open circles represent oxaliplatin and the vehicle, 
respectively. Data are presented as mean and standard error of the mean (n = 6). *P < 0.05 
compared to vehicle (Tukey's honestly significant difference test). 
 
Fig. 2  Effects of goshajinkigan on oxaliplatin-induced mechanical allodynia. Mice were 
injected intraperitoneally with oxaliplatin (3 mg/kg) on day 0. Goshajinkigan (0.1, 0.3, or 1.0 
g/kg) or vehicle (5% gum arabic) was administered orally day 10 after oxaliplatin injection. 
Mechanical allodynia was examined as described in the legend for Fig. 1. Data are presented as 
mean and standard error of the mean (n = 6). *P < 0.05 compared to vehicle (Tukey's honestly 
significant difference test). 
 
Fig. 3  Effects of neurotoxins on the levels of monoamine in the spinal cord and the inhibitory 
action of goshajinkigan (GJG) on oxaliplatin-induced mechanical allodynia. Mice were injected 
intraperitoneally with oxaliplatin (3 mg/kg). After 10 days, GJG (1.0 g/kg) or vehicle (VH1) was 
administered orally. 6-Hydroxydopamine hydrochloride (6-OHDA, 20 μg/site), 
5,7-Dihydroxytryptamine creatinine sulfate (5,7-DHT, 60 μg/site), vehicle for 6-OHDA (VH2), 
and vehicle for 5,7-DHT (VH3) were injected intrathecally 3 days before GJG administration. 
Mechanical allodynia was examined as described in the legend for Fig. 1. (A and B) 
Experimental schedules. (C and D) The effects of intrathecal treatment with 6-OHDA (C) and 
5,7-DHT (D) on the levels of noradrenaline (NA), dopamine (DA), and 5-hydroxytryptamine 
(5-HT) in the spinal cord. (E and F) Effects of intrathecal treatment with 6-OHDA (E) and 
5,7-DHT (F) on the antiallodynic action of GJG. Data are presented as mean and standard error of 
the mean (n = 5–6). *P < 0.05 compared to VH1+VH2 or VH1+VH3 (Dunnett's test in C and D 
and Tukey's honestly significant difference test in E and F). 
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ABSTRACT 
 
Peripheral neuropathy is a major dose-limiting side effect of the chemotherapeutic agent 
paclitaxel. This study examined whether the three related traditional herbal formulations 
goshajinkigan (GJG: 牛車腎氣丸 niú chē shèn qì wán), hachimijiogan (HJG: 八味地黃丸 bā 
wèi dì huáng wán), and rokumigan (RMG: 六味丸 liù wèi wán) would relieve 
paclitaxel-induced mechanical allodynia in mice. A single intraperitoneal injection of paclitaxel 
(5 mg/kg) induced mechanical allodynia, which peaked on day 14 after injection. On day 14 after 
paclitaxel injection, oral administration of GJG (0.1–1.0 g/kg) produced a significant inhibition of 
established allodynia, but HJG and RMG did not affect the allodynia. Repeated oral 
administration of GJG (0.1–1.0 g/kg) begining the day after paclitaxel injection did not affect 
allodynia development but significantly inhibited allodynia exacerbation. Repeated oral 
administration of HJG produced a slight inhibition of allodynia exacerbation, but that of RMG 
did not. These results suggest that prophylactic administration of GJG is effective in preventing 
the exacerbation of paclitaxel-induced allodynia. The herbal medicines Plantaginis Semen (車前
子 chē qián zǐ) and Achyranthis Radix (牛膝 niú xī), which are present in GJG but not in HJG, 
may contribute to the inhibitory action of GJG on the exacerbation of paclitaxel-induced 
allodynia. 
 
Key words: Paclitaxel, Mechanical allodynia, Goshajinkigan, Hachimijiogan, Rokumigan 
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INTRODUCTION 
 
Paclitaxel, an anti-microtubule agent originally isolated from the bark of the Pacific yew tree 
(Taxus brevifolia), is widely used to treat solid neoplasms such as ovarian, breast, and lung 
cancer.[1,2] However, paclitaxel causes peripheral neuropathy, which is characterized by pain and 
allodynia, with a stocking-and-glove distribution.[3] The peripheral neuropathy is a major 
dose-limiting side effect of paclitaxel. Several drugs, such as gabapentin and amifostine, were 
tested and failed to relieve paclitaxel-induced peripheral neuropathy in patients.[4–6] 
Goshajinkigan (GJG: 牛車腎氣丸 niú chē shèn qì wán) is a traditional herbal formulation 
consisting of 10 herbal medicines (Rehmanniae Radix (地黃 dì huáng), Achyranthis Radix (牛膝 
niú xī), Corni Fructus (山茱萸 shān zhū yú), Dioscoreae Rhizoma (山藥 shān yào), Plantaginis 
Semen (車前子 chē qián zǐ), Alismatis Rhizoma (沢瀉 zé xiè), Poria (茯苓 fú ling), Moutan 
Cortex (牡丹皮 mǔ dān pí), Cinnamoni Cortex (桂皮 guì pí), and Processi Aconiti Radix (附子 
fù zǐ). GJG is used for the treatment of several neurological symptoms including pain and 
dysesthesia (unpleasant abnormal sensation). GJG has been demonstrated to be effective against 
chemotherapy-induced peripheral neuropathy in cancer patients.[7,8] Recent studies have shown 
that GJG does not attenuate the antineoplastic action of chemotherapeutic agents.[9,10] Excluding 
Achyranthis Radix and Plantaginis Semen, hachimijiogan (HJG: 八味地黃丸 bā wèi dì huáng 
wán) consists of the same herbal medicines found in GJG, and rokumigan (RMG: 六味丸 liù 
wèi wán) consists of all herbal medicines found in HJG, excluding Cinnamoni Cortex and 
Processi Aconiti Radix. There is no clinical evidence of the effects of HJG and RMG on 
chemotherapy-induced peripheral neuropathy. In this study, we investigated the effects of GJG, 
HJG, and RMG on paclitaxel-induced mechanical allodynia. 
 
 
MATERIALS AND METHODS 
 
Animals 
Male C57BL/6NCr mice (Japan SLC Ltd., Hamamatsu, Japan) were used. All animals were 6 
weeks old at the start of the experiments. They were housed in a room with controlled 
temperature (21–23°C), humidity (45–65%), and a 12-hour light/dark cycle (lights on from 7:00 
am to 7:00 pm). Food and water were provided ad libitum. Experiments were performed after 
approval by the animal care committee of the University of Toyama.  
 
Drugs 
Paclitaxel purchased from Sigma-Aldrich (St. Louis, MO, USA) was dissolved in vehicle 
(physiological saline containing 10% Cremophor® EL (Sigma-Aldrich) and 10% ethanol). 
Paclitaxel and the vehicle were administered intraperitoneally; the dose (5 mg/kg) was selected 
from a published report[11] and was in accordance with the recommended clinical dose of 210 
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mg/m2 body surface area, which corresponds to a dose of 5.9 mg/kg in a person of 170 cm body 
height and 60 kg weight. Dried extracts of GJG (Lot. No. 2080107010, 2009), HJG (Lot. No. 
2090007010, 2009), and RMG (Lot. No. 2090087010, 2009) were obtained from Tsumura & Co., 
Ltd. (Tokyo, Japan). These dried extracts were dissolved in 5% gum Arabic and were 
administered orally once on day 14 after the paclitaxel injection or once daily from the day after 
the paclitaxel injection. 
 
Behavioral experiments 
Mechanical allodynia in the hind paw was evaluated using a von Frey filament (North Coast 
Medical Inc., Morgan Hill, CA, USA) as described.[11] After an acclimation period of at least 30 
min, a fine von Frey filament with a bending force of 0.69 mN was applied perpendicularly 
against the central part of the plantar hind paw and was held for 1–3 s with it slightly bent. 
Responses to the stimuli were scored as follows: 0, no reaction; 1, lifting of the hind paw; and 2, 
licking and flinching of the hind paw. A stimulus of the same intensity was applied three times 
alternately to each hind paw at intervals of several seconds, and the average response score 
served as the allodynia score (the maximum score was 2). When the effects of single 
administration of dried extracts of traditional formulations were examined on day 14 after 
paclitaxel injection, mechanical allodynia was evaluated before and after the administration of 
traditional formulations. When the effects of repeated administrations of the dried extracts were 
examined, mechanical allodynia evaluation was performed before each administration of 
traditional formulations. 
 
Statistical analysis 
 All data are presented as mean ± standard error of the mean. Statistical significance was 
analyzed using two-way repeated measures analysis of variance (ANOVA) and post hoc 
Holm-Sidak multiple comparison test. A P value < 0.05 was considered statistically significant. 
The statistical analyses were performed using SigmaPlot™ graphing and statistical software 
version 11 (Systat Software, Inc., Chicago, IL, USA). 
 
 
RESULTS 
 
Paclitaxel-induced mechanical allodynia 
A single intraperitoneal injection of paclitaxel (5 mg/kg) caused mechanical allodynia, which 
became apparent on day 4 after injection, peaked on day 14, and almost subsided by day 21 (Fig. 
1A): Main effect of paclitaxel treatment, F1,10 = 87.676, P < 0.001; interaction between paclitaxel 
treatment and time, F30,300 = 12.286, P <0.001 (two-way repeated measures ANOVA). 
 
Effects of single administration of GJG, HJG, and RMG on paclitaxel-induced mechanical 
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allodynia 
Three formulations were administered orally on day 14 after paclitaxel injection. Single 
administration of GJG (0.1–1.0 g/kg) exerted a relatively short-lasting but significant 
dose-dependent inhibition on established mechanical allodynia; two-way repeated measures 
ANOVA revealed a significant main effect of GJG (F3, 20 = 3.611, P = 0.031) (Fig. 1B). Single 
administration of HJG and RMG did not affect established mechanical allodynia at doses of 
0.1–1.0 g/kg (Fig. 1C and D). 
 
Effects of prophylactic administration of GJG, HJG, and RMG on paclitaxel-induced 
mechanical allodynia 
In this series of experiments, three formulations were administered daily from the day after 
paclitaxel injection. Repeated administration of GJG (0.1–1 g/kg) did not affect the initial 
development of mechanical allodynia induced by paclitaxel, but it significantly inhibited the 
exacerbation of allodynia from day 9 after paclitaxel injection, in comparison with the vehicle, 
although no clear dose-dependency was observed (Fig. 2A): Interaction between paclitaxel 
treatment and time, F42,252 = 1.889, P = 0.002 (two-way repeated measures ANOVA). Similarly, 
repeated administration of HJG (0.1–1 g/kg) did not affect the initial development of mechanical 
allodynia, but the highest dose of HJG (1 g/kg) significantly inhibited allodynia on day 14 after 
the injection, in comparison with the vehicle (Fig. 2B): Interaction between paclitaxel treatment 
and time, F42,266 = 1.504, P = 0.03 (two-way repeated measures ANOVA). Repeated 
administration of RMG (0.1–1 g/kg) did not affect mechanical allodynia induced by paclitaxel 
(Fig. 2C). 
 
 
DISCUSSION 
 
Single oral administration of GJG (0.1–1 g/kg) exerted a dose-dependent inhibition on 
established mechanical allodynia after paclitaxel injection, whereas the GJG-related herbal 
formulations HJG and RMG did not affect the established allodynia. The recommended clinical 
daily dose of GJG granules is 7.5 g, which contains 4.5 g of dried GJG extract. Given that the 
body weight is 60 kg, the dose of the dried GJG extract is 0.075 g/kg. Thus, the antiallodynic 
dose (1 g/kg) in mice with paclitaxel-induced neuropathy was 13 times higher than the 
recommended clinical dose. Recently, we have demonstrated that single oral administration of 
GJG (0.3 and 1.0 g/kg) inhibits established mechanical allodynia after the injection of oxaliplatin, 
a platinum chemotherapeutic agent.[12] The inhibitory effect of 1 g/kg GJG on paclitaxel-induced 
allodynia (present experiments) was less than that of 0.3 g/kg GJG on oxaliplatin-induced 
allodynia.[12] The inhibitory action of GJG on oxaliplatin-induced allodynia is at least in part 
mediated by the activation of the descending noradrenergic and serotonergic systems,[12] and in 
our preliminary experiment, single administration of milnacipran, a serotonin–noradrenaline 
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reuptake inhibitor, markedly inhibited established allodynia after oxaliplatin injection (data not 
shown). In contrast, single administration of milnacipran does not affect established allodynia 
after paclitaxel injection.[13] These findings, taken together, raise the possibility that a low 
efficacy of GJG in paclitaxel-induced allodynia is due to the decreased activity of the descending 
noradrenergic and serotonergic systems. It is possible that paclitaxel decreases the activity of the 
descending noradrenergic and/or serotonergic systems. 
Prophylactic repeated administration of GJG inhibited paclitaxel-induced mechanical 
allodynia. GJG consists of the following 10 herbal medicines: Rehmanniae Radix, Corni Fructus, 
Dioscoreae Rhizoma, Alismatis Rhizoma, Poria, Moutan Cortex, Cinnamoni Cortex, Processi 
Aconiti Radix, Achyranthis Radix, and Plantaginis Semen; HJG consists of the first 8 of these 
herbal medicines; and RMG consists of the first 6 of these medicines. The results showed that 
HJG had only a slight effect at the highest dose tested, and RMG did not have a prophylactic 
effect, suggesting that Plantaginis Semen and/or Achyranthis Radix play a role in the prophylactic 
activity of GJG. The underlying mechanisms are unclear, and allodynia-preventing substances 
have not yet been isolated from the extracts of these two herbal medicines. However, one 
possibility is that the activity of the scavengers of reactive oxygen species is involved in the 
antiallodynic activity. Although a single administration is ineffective, prophylactic administration 
of the reactive oxygen species scavenger N-tert-butyl-aphenylnitrone suppresses 
paclitaxel-induced mechanical allodynia.[14] Since Plantaginis Semen and Achyranthis Radix have 
antioxidant activity,[15-17] this action may be involved in the prevention of an exacerbation of 
paclitaxel-induced allodynia. Another possibility is the improvement of decreased blood flow. 
Paclitaxel, but not vincristine, decreases peripheral blood flow.[11] The prostaglandin E1 analogue 
limaprost, which counteracts this reduction in blood flow without affecting normal blood flow,[18] 
exerts prophylactic inhibition on allodynia induced by paclitaxel, but not by vincristine.11) In this 
study, prophylactic administration of GJG prevented mechanical allodynia induced by paclitaxel. 
In contrast, in our preliminary experiments, prophylactic administration of GJG did not prevent 
vincristine-induced allodynia. GJG and its constituent Achyranthis Radix invigorate blood 
circulation.[15,17,19] Taken together, these findings raise the possibility that the prevention of the 
decrease in peripheral blood flow contributes to the prophylactic activity of GJG. 
Prophylactic administration of HJG, but not RMG, showed slight antiallodynic action at the 
highest dose tested in paclitaxel-treated mice. Thus, it is possible that Cinnamoni Cortex and 
Processi Aconiti Radix also have prophylactic antiallodynic activity. Similar to Achyranthis Radix, 
Cinnamoni Cortex and Processi Aconiti Radix invigorate blood circulation.[20,21] However, the 
prophylactic antiallodynic activity of HJG was weaker than that of GJG. Thus, although 
Cinnamoni Cortex and Processi Aconiti Radix may have some prophylactic antiallodynic activity, 
Plantaginis Semen and Achyranthis Radix may play important roles in the antiallodynic action of 
GJG. 
In conclusion, prophylactic administration of GJG prevents an exacerbation of 
paclitaxel-induced mechanical allodynia. Since GJG also has acute antiallodynic activity, it may 
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be useful for the prevention of paclitaxel-induced peripheral neuropathy. Although the underlying 
mechanisms remain unclear, Plantaginis Semen and/or Achyranthis Radix may contribute to the 
antiallodynic activity of GJG. 
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Figure legends 
 
Figure 1.  Effects of single administration of goshajinkigan (GJG), hachimijiogan (HJG), and 
rokumigan (RMG) on established mechanical allodynia after paclitaxel injection. (A) 
Development of mechanical allodynia after a single injection of paclitaxel. Mice were injected 
intraperitoneally with paclitaxel (5 mg/kg) or vehicle on day 0. GJG (B), HJG (C), RMG (D), or 
vehicle (5% gum arabic) was orally administered day 14 after paclitaxel injection. Data are 
presented as mean and standard error of the mean (n = 5–6). *P < 0.05 compared to vehicle 
(Holm-Sidak multiple comparisons). 
 
 
Figure 2.  Effects of prophylactic administrations of goshajinkigan (GJG), hachimijiogan (HJG), 
and rokumigan (RMG) on paclitaxel-induced mechanical allodynia. Paclitaxel (5 mg/kg) was 
injected intraperitoneally in mice, and GJG (A), HJG (B), RMG (C), or vehicle (5% gum arabic) 
was administered orally once daily from the day after the paclitaxel injection. Data are presented 
as mean and standard error of the mean (n = 5–6). *P < 0.05 compared to vehicle (Holm-Sidak 
multiple comparisons). 
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